Scorpion Therapeutics Funding: $515M Raised, Series D (2025)
Scorpion Therapeutics is a Biotech company based in Boston. It has raised $515M in total funding. Latest round: Series D. Backed by Atlas Venture, Lilly.
Scorpion Therapeutics funding overview
Scorpion Therapeutics is a Biotech company based in Boston. Scorpion Therapeutics has raised $515M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in May 2025. The round record for Scorpion Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Atlas Venture, Lilly. 2 distinct backers are named across the disclosed rounds.
Scorpion Therapeutics at a glance
Total raised
$515M
Latest round
Series D
Latest round date
May 2025
Industry
Biotech
Headquarters
Boston
Notable investors
Atlas Venture, Lilly
Frequently asked about Scorpion Therapeutics funding
How much has Scorpion Therapeutics raised?
Scorpion Therapeutics has raised $515M in total disclosed funding across the rounds on record.
Who has invested in Scorpion Therapeutics?
Atlas Venture, Lilly are named among the investors backing Scorpion Therapeutics.
What was the latest Scorpion Therapeutics funding round?
The most recent disclosed round is a Series D, announced in May 2025.
Where is Scorpion Therapeutics based?
Scorpion Therapeutics is based in Boston.
What sector does Scorpion Therapeutics operate in?
Scorpion Therapeutics is tracked under Biotech from Boston, with $515M in disclosed funding.
When did Scorpion Therapeutics last raise?
The last disclosed Scorpion Therapeutics round closed in May 2025 at Series D.
Scorpion Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Boston below to benchmark round size and investor mix.
